New Reagents on the Horizon for Immune Tolerance
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Recent advances in immunology and a growing arsenal of new drugs are bringing the focus of tolerance research from animal models into the clinical setting. The conceptual framework for therapeutic tolerance induction has shifted from a “sledgehammer” approach that relies solely on cellular depletion and cytokine targeting, to a strategy directed toward restoring a functional balance across the immune system, namely the different populations of naive cells, effector and memory cells, and regulatory cells. Unlocking the key to tolerance induction in the future will likely depend on our ability to harness the functions of T regulatory cells. Also, dendritic cells are strategically positioned at the interface between innate and adaptive immunity and may be subject to deliberate medical intervention in a way that can control a chronic inflammatory response. Many reagents with tolerance-inducing potential are currently undergoing clinical testing in transplantation, autoimmune diseases, and allergic diseases, and even more that are on the horizon promise to offer enormous benefits to human health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623 · cited 2×
“Rituximab therapy has been shown to reduce the signs and symptoms of RA, and it achieves variable decreases in the serum levels of rheumatoid factor without significantly altering serum levels of IgM, IgG, and IgA (64).”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Th17: An Effector CD4 T Cell Lineage with Regulatory T Cell Ties
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.002 · Cited by 1,422 · cited 1×
“Th17 cells, so named because they produce IL-17, participate in the control of certain infectious diseases and autoimmune syndromes (17).”
BackgroundAnti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citationInsulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Möller, C., Dreborg, S., Ferdousi, H. A., Halken, S., Høst, A., Jacobsen, L., Koivikko, A., Koller, D. Y., Niggemann, B., Norberg, L. A., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121317 · Cited by 1,065
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833 · cited 1×
“In humans, when antiCTLA-4 antibodies are used for cancer therapy, they often provoke autoimmune diseases of the endocrine organs, gastrointestinal tract and skin (11).”
BackgroundEffects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668 · cited 1×
“However, in nondiabetic relatives with high titers of insulin autoantibodies (a subpopulation with a high rate of disease progression), there is preliminary evidence that oral insulin therapy reduces the incidence of diabetes development (71).”
BackgroundDefective regulatory and effector T cell functions in patients with FOXP3 mutations
Bacchetta, R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25112 · Cited by 511 · cited 1×
“In some of these patients, the effector CD4+CD25− T cells show reduced susceptibility to suppression (21).”
Background
Cited by
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Self-citationCD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Self-citationHuman regulatory T cells: role in autoimmune disease and therapeutic opportunities
Brusko, T. M., Putnam, A. L., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00637.x · Cited by 374
Self-citationExpansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes
Putnam, A. L., Brusko, T. M., Lee, M. R., Liu, W., Szot, G. L., Ghosh, T., Atkinson, M. A., & Bluestone, J. A. (2009) · Diabetes · doi:10.2337/db08-1168 · Cited by 357
Self-citationMechanism of cellular rejection in transplantation
Ingulli, E. (2010) · Pediatric Nephrology · doi:10.1007/s00467-008-1020-x · Cited by 313
Metadata
- Authors
- St. Clair, E. W., Turka, L. A., Saxon, A., Matthews, J. B., Sayegh, M. H., Eisenbarth, G. S., & Bluestone, J.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2007-02-01
- Volume
- 58
- Issue
- 1
- Pages
- 329-346
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2128559223
- Cited by
- 62
- References
- 14
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Reagents on the Horizon for Immune Tolerance. https://app.cochat.ai/papers/10.1146/annurev.med.58.061705.145449
- The paper
- St. Clair, E. W., Turka, L. A., Saxon, A., Matthews, J. B., Sayegh, M. H., Eisenbarth, G. S., & Bluestone, J. (2007). New Reagents on the Horizon for Immune Tolerance. Annual Review of Medicine. https://doi.org/10.1146/annurev.med.58.061705.145449
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.